In the ASSessing the effect of Anti-IL-6 treatment in Myocardial Infarction (ASSAIL-MI) trial, we showed that a single dose of the interleukin (IL)-6 receptor inhibitor tocilizumab attenuated myocardial injury in patients with acute STEMI. The gene discussed is IL6; the disease is myocardial infarction.